ArticleClinical rheumatology2026
Machine learning based on systemic inflammation response index and risk of cardiovascular disease in gout: a retrospective study and clinical validation.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveGout is a chronic inflammatory disease, and cardiovascular disease (CVD) is regarded as one of its complications. The aim of our study was to explore the association between systemic inflammation response index (SIRI) and the risk of CVD in gout.
methodsSix cycles of NHANES data were analyzed. Machine learning algorithms were employed to screen covariates, followed by SHAP interpretation to assess variable importance. Participants with gout were stratified by SIRI quartiles, and logistic regression was performed to evaluate CVD risk. RCS were applied to assess nonlinear trends, while discrimination, calibration, and clinical utility were evaluated using ROC, DCA, and calibration curve. Additionally, the Framingham risk score (FRS) model was integrated with SIRI, and model improvement was quantified via net reclassification improvement and integrated discrimination improvement.
resultsAmong 1260 participants with gout, 436 (weighted 28.77%) had CVD comorbidities. A linear positive association was observed between SIRI and CVD risk (P for nonlinear = 0.824), with each 1-unit increase in SIRI corresponding to 29.7% higher CVD risk (OR = 1.297, 95% CI 1.073-1.568). Participants in the highest SIRI quartile Q4 (OR = 2.060, 95% CI 1.141-3.721) exhibited increased CVD risk compared to Q1. The final model demonstrated robust discrimination (AUC = 0.755, 95% CI 0.729-0.783). Incorporating SIRI into the NHANES and clinical datasets improved the discrimination of the FRS model by 5.2% and 1.9%.
conclusionA positive linear association was identified between SIRI and CVD risk in gout patients. The model constructed based on machine learning demonstrated comparable robustness to the FRS model in predicting CVD. These findings provide a theoretical and empirical foundation for early CVD identification, prevention, and management in this population. Key Points • The positive linear association between the systemic inflammation response index and cardiovascular disease, as well as its subtypes in patients with gout. • SIRI can serve as a valuable complement to the Framingham risk score model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.